Citation Impact
Citing Papers
Effect of Clopidogrel Added to Aspirin in Patients with Atrial Fibrillation
2009 Standout
Hypoxic control of metastasis
2016 Science
Rationally Designed Integrin β3 Mutants Stabilized in the High Affinity Conformation
2008 StandoutNobel
Risk of Cardiovascular Events Associated With Selective COX-2 Inhibitors
2001
Modulation of Integrin Activation by an Entropic Spring in the β-Knee
2010 StandoutNobel
Platelets: Physiology and Biochemistry
2005
Mechanisms of Thrombus Formation
2008 Standout
Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities
2005
Heparin and Low-Molecular-Weight Heparin Mechanisms of Action, Pharmacokinetics, Dosing, Monitoring, Efficacy, and Safety
2001 Standout
von Willebrand Factor–Cleaving Protease in Thrombotic Thrombocytopenic Purpura and the Hemolytic–Uremic Syndrome
1998 Standout
Association Between Naproxen Use and Protection Against Acute Myocardial Infarction
2002
The role of tissue factor in the antiphospholipid syndrome
2001
CD22 blockade restores homeostatic microglial phagocytosis in ageing brains
2019 StandoutNatureNobel
Mechanisms linking obesity with cardiovascular disease
2006 StandoutNature
Cell Signaling by Receptor Tyrosine Kinases
2010 Standout
Aspirin, Heparin, and Fibrinolytic Therapy in Suspected Acute Myocardial Infarction
1997
Risk of cardiovascular events and rofecoxib: cumulative meta-analysis
2004
Comparison of Upper Gastrointestinal Toxicity of Rofecoxib and Naproxen in Patients with Rheumatoid Arthritis
2000 Standout
Cardiovascular Events Associated with Rofecoxib in a Colorectal Adenoma Chemoprevention Trial
2005 Standout
Macrophages in the Pathogenesis of Atherosclerosis
2011 Standout
Platelet-Active Drugs
1998
Integration of Proteomics and Genomics in Platelets
2003
Phagocytosis of apoptotic cells in homeostasis
2015
Clinical effects of anticoagulant therapy in suspected acute myocardial infarction: systematic overview of randomised trials
1996
Shiga-toxin-producing Escherichia coli and haemolytic uraemic syndrome
2005 Standout
Temporal Aspects of Heparin-Induced Thrombocytopenia
2001 Standout
Effect of Selective Cyclooxygenase 2 Inhibitors and Naproxen on Short-term Risk of Acute Myocardial Infarction in the Elderly
2003
TAM receptors regulate multiple features of microglial physiology
2016 Nature
Minding the gaps to promote thrombus growth and stability
2005
TAM Receptors Are Pleiotropic Inhibitors of the Innate Immune Response
2007
Genetic models for the clearance of apoptotic cells
2004
Cardiovascular Risk Associated with Celecoxib in a Clinical Trial for Colorectal Adenoma Prevention
2005 Standout
COX-2 and beyond: approaches to prostaglandin inhibition in human disease
2003
Redirection of prostaglandin endoperoxide metabolism at the platelet-vascular interface in man.
1989
Platelet Activation and Atherothrombosis
2007 Standout
Lower Risk of Thromboembolic Cardiovascular Events With Naproxen Among Patients With Rheumatoid Arthritis
2002
Coxibs and Cardiovascular Disease
2004 Standout
Potent and selective inhibition of HIV-1 replication in vitro by a novel series of TIBO derivatives
1990 Nature
Structural basis for Gas6–Axl signalling
2005
Systemic Lupus Erythematosus
2011 Standout
Pentosan polysulfate‐induced thrombocytopenia and thrombosis
1994
Emerging Biological Principles of Metastasis
2017 Standout
Crystal structure of an HIV-binding recombinant fragment of human CD4
1990 StandoutNatureNobel
Heparin-Induced Thrombocytopenia in Patients Treated with Low-Molecular-Weight Heparin or Unfractionated Heparin
1995 Standout
Platelet GPIIb/IIIa antagonists: the first anti-integrin receptor therapeutics.
1997
HIV as the cause of AIDS
1996 StandoutNobel
Origin and physiological roles of inflammation
2008 StandoutNature
Comparison of cardiovascular thrombotic events in patients with osteoarthritis treated with Rofecoxib versus nonselective nonsteroidal anti-inflammatory drugs (Ibuprofen, Diclofenac, and Nabumetone)
2002
Angiotensin II Type 1–Receptor Activating Antibodies in Renal-Allograft Rejection
2005 Standout
Nonsteroidal Anti-Inflammatory drugs and cardiovascular risk
2004
Progress and challenges in translating the biology of atherosclerosis
2011 StandoutNature
Cyclooxygenases, microsomal prostaglandin E synthase-1, and cardiovascular function
2006
Cyclosporine
1989 Standout
The P2Y12 receptor regulates microglial activation by extracellular nucleotides
2006 StandoutNobel
The Coxibs, Selective Inhibitors of Cyclooxygenase-2
2001
The pathophysiology and management of thrombotic thrombocytopenic purpura
1996
Platelets in atherothrombosis: lessons from mouse models
2005
Cyclooxygenase Inhibitors and the Antiplatelet Effects of Aspirin
2001 Standout
Low-dose ASA Response Using the PFA-100 in Women With High-risk Pregnancy
2009
Integrins
2002 Standout
Arterial thrombosis—insidious, unpredictable and deadly
2011
A Comparison of Enoxaparin with Placebo for the Prevention of Venous Thromboembolism in Acutely Ill Medical Patients
1999 Standout
Aspirin versus Placebo in Pregnancies at High Risk for Preterm Preeclampsia
2017 Standout
The pathogenesis of atherosclerosis: a perspective for the 1990s
1993 StandoutNature
Protein therapeutics: a summary and pharmacological classification
2007 Standout
Selective COX-2 inhibition and cardiovascular effects: a review of the rofecoxib development program
2003
Bifidobacteria can protect from enteropathogenic infection through production of acetate
2011 StandoutNature
Synthesis of Heterobifunctional Protein Fusions Using Copper‐Free Click Chemistry and the Aldehyde Tag
2012 StandoutNobel
Platelet CD36 links hyperlipidemia, oxidant stress and a prothrombotic phenotype
2007
Thrombosis as an intravascular effector of innate immunity
2012 Standout
Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial
2004
Platelet-Active Drugs
2001
Platelet-Active Drugs: The Relationships Among Dose, Effectiveness, and Side Effects
2004
P2Y12 regulates platelet adhesion/activation, thrombus growth, and thrombus stability in injured arteries
2003
Leptin-dependent platelet aggregation and arterial thrombosis suggests a mechanism for atherothrombotic disease in obesity
2001
HIV-1 Integrase: High-Level Production and Screening Assay for the Endonucleolytic Activity
1992
Inhibition of Platelet Glycoprotein IIb/IIIa with Eptifibatide in Patients with Acute Coronary Syndromes
1998 Standout
Characterization of the proteins released from activated platelets leads to localization of novel platelet proteins in human atherosclerotic lesions
2003
Audit and feedback: effects on professional practice and healthcare outcomes
2012 Standout
Efficacy of a Synthetic Pentasaccharide, a Pure Factor Xa Inhibitor, as an Antithrombotic Agent – A Pilot Study in the Setting of Coronary Angioplasty
1999
Eph kinases and ephrins support thrombus growth and stability by regulating integrin outside-in signaling in platelets
2005
HIV Population Dynamics in Vivo: Implications for Genetic Variation, Pathogenesis, and Therapy
1995 StandoutScience
Molecular Targets for AIDS Therapy
1990 Science
Sera from patients with heparin-induced thrombocytopenia generate platelet-derived microparticles with procoagulant activity: an explanation for the thrombotic complications of heparin-induced thrombocytopenia
1994
The GPIIb/IIIa (integrin αIIbβ3) odyssey: a technology-driven saga of a receptor with twists, turns, and even a bend
2008
Defective thrombus formation in mice lacking coagulation factor XII
2005
Structure of the binding site for nonnucleoside inhibitors of the reverse transcriptase of human immunodeficiency virus type 1.
1994 StandoutNobel
THROMBOEMBOLIC COMPLICATIONS AND HAEMOSTATIC CHANGES IN CYCLOSPORIN-TREATED CADAVERIC KIDNEY ALLOGRAFT RECIPIENTS
1985
Crystal Structure at 3.5 Å Resolution of HIV-1 Reverse Transcriptase Complexed with an Inhibitor
1992 StandoutScience
Platelet aggregation induces platelet aggregate stability via SLAM family receptor signaling
2005
Mechanisms of platelet activation: Thromboxane A2 as an amplifying signal for other agonists
1991
Structure of a Covalently Trapped Catalytic Complex of HIV-1 Reverse Transcriptase: Implications for Drug Resistance
1998 StandoutScience
1 Arachidonate Metabolism in Blood Cells and the Vessel Wall
1986
Guide to anticoagulant therapy. Part 1: Heparin. American Heart Association.
1994
Prostaglandins and Leukotrienes: Advances in Eicosanoid Biology
2001 StandoutScience
Challenges of Establishing New Antithrombotic Therapies in Atrial Fibrillation
2007
Site-specific chemical modification of recombinant proteins produced in mammalian cells by using the genetically encoded aldehyde tag
2009 StandoutNobel
How neuroinflammation contributes to neurodegeneration
2016 StandoutScience
Use of a Standardized Heparin Nomogram to Achieve Therapeutic Anticoagulation After Thrombolytic Therapy in Myocardial Infarction
1994
Role of Prostacyclin in the Cardiovascular Response to Thromboxane A 2
2002 StandoutScience
Pathogenesis of human immunodeficiency virus infection
1993
Anti-GPIIb/IIIa Drugs: Current Strategies and Future Directions
2001
A platelet-activating factor antagonist, RP 55778, inhibits cytokine-dependent induction of human immunodeficiency virus expression in chronically infected promonocytic cells.
1993 StandoutNobel
Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination
2021 Standout
A soluble form of the Mer receptor tyrosine kinase inhibits macrophage clearance of apoptotic cells and platelet aggregation
2006
Inhibitors of human immunodeficiency virus integrase.
1993 StandoutNobel
Intravascular tissue factor initiates coagulation via circulating microvesicles and platelets
2003
Effects of Platelet Glycoprotein IIb/IIIa Blockade With Tirofiban on Adverse Cardiac Events in Patients With Unstable Angina or Acute Myocardial Infarction Undergoing Coronary Angioplasty
1997
Prevention of HIV-1 Infection and Preservation of CD4 Function by the Binding of CPFs to gp120
1990 Science
Cardiovascular Thrombotic Events in Controlled, Clinical Trials of Rofecoxib
2001
The risk of cardiovascular thrombotic events with selective cyclooxygenase‐2 inhibitors
2002
Works of Jef Arnout being referenced
Pharmacokinetics and pharmacodynamics of MK-383, a selective non-peptide platelet glycoprotein-IIb/IIIa receptor antagonist, in healthy men
1994
Activation of both coagulation and fibrinolysis in childhood hemolytic uremic syndrome
1998
A new lupus anticoagulant neutralization test based on platelet‐derived vesicles
1992
Role of proaggregatory and antiaggregatory prostaglandins in hemostasis. Studies with combined thromboxane synthase inhibition and thromboxane receptor antagonism.
1987
Effects of enteric‐coated, low‐dose aspirin on parameters of platelet function
2002
The Belgian Improvement Study on Oral Anticoagulation Therapy: a randomized clinical trial
2005
Deficiency or inhibition of Gas6 causes platelet dysfunction and protects mice against thrombosis
2001
Correlation between level of heparinization and patency of the infarct-related coronary artery after treatment of acute myocardial infarction with alteplase (rt-PA)
1992
Dipyridamole Inhibits Platelet Aggregation in Whole Blood
1983
A Higher than Expected Incidence of Factor VIII Inhibitors in Multitransfused Haemophilia A Patients Treated with an Intermediate Purity Pasteurized Factor VIII Concentrate
1993
Mechanism of inhibitory effect of dextran sulfate and heparin on replication of human immunodeficiency virus in vitro.
1988
BM 13.177, A SELECTIVE BLOCKER OF PLATELET AND VESSEL WALL THROMBOXANE RECEPTORS, IS ACTIVE IN MAN
1984
Comparative Inhibitory Activity of Rofecoxib, Meloxicam, Diclofenac, Ibuprofen, and Naproxen on COX‐2 versus COX‐1 in Healthy Volunteers
2000
Comparison of a Synthetic Antithrombin III-binding Pentasaccharide and Standard Heparin as an Adjunct to Coronary Thrombolysis
1998
Antibody-Mediated Thrombosis
1997
Anti-factor VIII antibodies of hemophiliac patients are frequently directed towards nonfunctional determinants and do not exhibit isotypic restriction
1993